| Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial (NCT07605416) | National Cancer Institute (NCI) | 2027-04-20 |
| Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) (NCT07437950) | National Cancer Institute (NCI) | 2027-04-18 |
| Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment (NCT07463807) | National Cancer Institute (NCI) | 2027-04-12 |
| Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma (NCT07332507) | National Cancer Institute (NCI) | 2027-03-26 |
| Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial (NCT07388524) | National Cancer Institute (NCI) | 2027-03-02 |
| Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma (NCT07156227) | National Cancer Institute (NCI) | 2027-02-13 |
| Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma (NCT07689240) | National Cancer Institute (NCI) | 2027-02-10 |
| Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial) (NCT06917911) | National Cancer Institute (NCI) | 2027-02-02 |
| Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma (NCT07572123) | National Cancer Institute (NCI) | 2026-12-04 |
| Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma (NCT07422363) | National Cancer Institute (NCI) | 2026-12-04 |
| Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma (NCT07281417) | National Cancer Institute (NCI) | 2026-11-24 |
| Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse (NCT07437963) | National Cancer Institute (NCI) | 2026-10-28 |
| AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") (NCT07649304) | National Cancer Institute (NCI) | 2026-10-09 |
| Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer (NCT07137416) | National Cancer Institute (NCI) | 2026-10-05 |
| Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones (NCT06982222) | National Cancer Institute (NCI) | 2026-10-01 |
| Testing the Anti-Cancer Drug, Brenetafusp (IMCF106C), in Rare Cancers (NCT07686367) | National Cancer Institute (NCI) | 2026-09-11 |
| Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy (NCT07504588) | National Cancer Institute (NCI) | 2026-09-10 |
| Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a, for Advanced Pancreatic Ductal Adenocarcinoma (NCT07619521) | National Cancer Institute (NCI) | 2026-09-08 |
| Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment (NCT06888323) | National Cancer Institute (NCI) | 2026-09-03 |
| Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse (NCT06948084) | National Cancer Institute (NCI) | 2026-08-26 |
| Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma (NCT06876142) | National Cancer Institute (NCI) | 2026-08-23 |
| IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy (NCT07686380) | National Cancer Institute (NCI) | 2026-08-23 |
| Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL) (NCT07572136) | National Cancer Institute (NCI) | 2026-08-23 |
| Combination Bevacizumab and PRGN-2012 in Adults With Recurrent Respiratory Papillomatosis (RRP) (NCT07756840) | National Cancer Institute (NCI) | 2026-08-23 |
| Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms (NCT06303193) | National Cancer Institute (NCI) | 2026-08-23 |
| Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance (NCT07574541) | National Cancer Institute (NCI) | 2026-08-23 |
| Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy (NCT07715903) | National Cancer Institute (NCI) | 2026-08-23 |
| A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity (NCT06406465) | National Cancer Institute (NCI) | 2026-08-23 |
| NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors (NCT07489378) | National Cancer Institute (NCI) | 2026-08-23 |
| Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases (NCT07619534) | National Cancer Institute (NCI) | 2026-08-23 |
| A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymph... (NCT05621291) | National Cancer Institute (NCI) | 2026-08-23 |
| Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) (NCT06694454) | National Cancer Institute (NCI) | 2026-08-23 |
| IL-12 Genetically Engineered Myeloid Cells in Participants With Relapsed, Refractory Solid Tumors (NCT07672483) | National Cancer Institute (NCI) | 2026-08-23 |
| Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer (NCT07667400) | National Cancer Institute (NCI) | 2026-08-23 |
| Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease (NCT07509034) | National Cancer Institute (NCI) | 2026-08-23 |
| Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma (NCT06487481) | National Cancer Institute (NCI) | 2026-08-23 |
| Clinical Genetics Branch Eligibility Screening Survey (NCT07005297) | National Cancer Institute (NCI) | 2026-08-23 |
| Natural History Study of Early Life Exposures in Agriculture (ELEA) (NCT07328516) | National Cancer Institute (NCI) | 2026-08-23 |
| Experience and Management of Cancer Screening-Related Anxiety in Fanconi Anemia (NCT06744283) | National Cancer Institute (NCI) | 2026-08-23 |
| Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers (NCT07524530) | National Cancer Institute (NCI) | 2026-08-23 |
| Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies (NCT06904066) | National Cancer Institute (NCI) | 2026-08-23 |
| Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial (NCT07516366) | National Cancer Institute (NCI) | 2026-08-21 |
| Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma (NCT07444710) | National Cancer Institute (NCI) | 2026-08-20 |
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma (NCT07724457) | National Cancer Institute (NCI) | 2026-08-14 |
| Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial (NCT07551596) | National Cancer Institute (NCI) | 2026-08-14 |
| Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer (NCT07147231) | National Cancer Institute (NCI) | 2026-08-10 |
| A Scientific Evaluation of One or Two Doses of a Vaccine Against Human Papillomavirus: Long Term Follow Up of Gardasil9 Recipients in the ESCUDDO Study ("Estudio de Comparación de Una y Dos Dosis de Vacunas Contra el Virus de Papiloma Humano [VPH]") (NCT07706673) | National Cancer Institute (NCI) | 2026-08-03 |
| Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) (NCT06954987) | National Cancer Institute (NCI) | 2026-07-17 |
| An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis (NCT06557733) | National Cancer Institute (NCI) | 2026-07-13 |
| Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy (NCT07003295) | National Cancer Institute (NCI) | 2026-07-08 |
| A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer (NCT07349641) | National Cancer Institute (NCI) | 2026-07-06 |
| Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) (NCT05554419) | National Cancer Institute (NCI) | 2026-07-01 |
| Testing the SurVaxM Vaccine for Lung Cancer Prevention (NCT07169617) | National Cancer Institute (NCI) | 2026-07-01 |
| Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus (NCT06732388) | National Cancer Institute (NCI) | 2026-06-23 |
| A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial) (NCT07463820) | National Cancer Institute (NCI) | 2026-06-19 |
| Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation (NCT07012031) | National Cancer Institute (NCI) | 2026-06-17 |
| A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia (NCT07012044) | National Cancer Institute (NCI) | 2026-06-09 |
| Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia (NCT06965114) | National Cancer Institute (NCI) | 2026-05-29 |
| Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event (NCT07499128) | National Cancer Institute (NCI) | 2026-05-27 |
| Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy) (NCT07153497) | National Cancer Institute (NCI) | 2026-05-27 |
| Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia (NCT07061951) | National Cancer Institute (NCI) | 2026-05-27 |
| Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer (NCT06980038) | National Cancer Institute (NCI) | 2026-05-27 |
| Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer (NCT07328490) | National Cancer Institute (NCI) | 2026-04-25 |
| Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer (NCT07195734) | National Cancer Institute (NCI) | 2026-04-24 |
| Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia (NCT06802523) | National Cancer Institute (NCI) | 2026-04-21 |
| Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV) (NCT07308886) | National Cancer Institute (NCI) | 2026-04-08 |
| Quality of Care for Adolescent and Young Adult (AYA) Patients Living With Serious or Advanced Cancer (NCT07484282) | National Cancer Institute (NCI) | 2026-04-07 |
| Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma (NCT07388563) | National Cancer Institute (NCI) | 2026-03-26 |
| Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System (NCT07042295) | National Cancer Institute (NCI) | 2026-03-23 |
| Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma (NCT06498648) | National Cancer Institute (NCI) | 2026-03-18 |
| Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma (NCT06654050) | National Cancer Institute (NCI) | 2026-03-16 |
| Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (NCT06856226) | National Cancer Institute (NCI) | 2026-03-04 |
| A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast) (NCT07067138) | National Cancer Institute (NCI) | 2026-02-23 |
| Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer (NCT06900595) | National Cancer Institute (NCI) | 2026-02-22 |
| A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1) (NCT06507748) | National Cancer Institute (NCI) | 2026-02-18 |
| CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer (NCT06730100) | National Cancer Institute (NCI) | 2026-02-17 |
| Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors (NCT07374692) | National Cancer Institute (NCI) | 2026-02-04 |
| Testing RG1-VLP Vaccine to Prevent HPV-related Cancers (NCT05985681) | National Cancer Institute (NCI) | 2026-01-27 |
| Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (NCT07198074) | National Cancer Institute (NCI) | 2026-01-27 |
| Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE) (NCT06041503) | National Cancer Institute (NCI) | 2026-01-20 |
| A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer (NCT06524544) | National Cancer Institute (NCI) | 2025-12-02 |
| Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial (NCT07061964) | National Cancer Institute (NCI) | 2025-11-25 |
| Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04) (NCT07281430) | National Cancer Institute (NCI) | 2025-11-24 |
| Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial (NCT06811116) | National Cancer Institute (NCI) | 2025-11-17 |
| Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation (NCT07162038) | National Cancer Institute (NCI) | 2025-11-14 |
| Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer (NCT07061977) | National Cancer Institute (NCI) | 2025-11-05 |
| A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing (NCT06066138) | National Cancer Institute (NCI) | 2025-11-04 |
| Testing for Safety and Colorectal Cancer Preventive Effects of ONC201 (NCT05630794) | National Cancer Institute (NCI) | 2025-10-06 |
| A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL) (NCT07055477) | National Cancer Institute (NCI) | 2025-09-29 |
| FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma (NCT06865664) | National Cancer Institute (NCI) | 2025-09-22 |
| A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer (NCT06410534) | National Cancer Institute (NCI) | 2025-09-09 |
| 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection (NCT06503146) | National Cancer Institute (NCI) | 2025-09-09 |
| A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies (NCT06690281) | National Cancer Institute (NCI) | 2025-09-09 |
| [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers (NCT06479811) | National Cancer Institute (NCI) | 2025-08-19 |
| Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC) (NCT06603818) | National Cancer Institute (NCI) | 2025-08-15 |
| Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes (NCT06484062) | National Cancer Institute (NCI) | 2025-08-15 |
| A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) (NCT06661915) | National Cancer Institute (NCI) | 2025-08-14 |
| Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer (NCT06732401) | National Cancer Institute (NCI) | 2025-08-07 |
| Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer (NCT06590558) | National Cancer Institute (NCI) | 2025-08-04 |
| Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma (NCT06860594) | National Cancer Institute (NCI) | 2025-07-30 |